Associated Papers
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
Lin KP et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2024
2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.
Wang CC et al.
Acta Cardiologica Sinica, 2023
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T et al.
Neurology and Therapy, 2023
Targeted Therapeutics for Transthyretin Cardiac Amyloidosis.
Shah SJ
Circulation, 2019
Select a paper to view details